NCT06587100 Wearable Activity Tracking to Curb Hospitalizations
| NCT ID | NCT06587100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Hematopoietic Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 260 participants |
| Start Date | 2025-04-07 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 260 participants in total. It began in 2025-04-07 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.
Eligibility Criteria
Inclusion Criteria: * Age \>= 18. * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2. * Able to understand study procedures and to comply with them for the entire length of the study. * Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it. * Diagnosis of invasive malignancy. * Able to ambulate independently (without the assistance of a cane or walker). * Planned treatment with fractionated external beam radiotherapy over at least 5 days (no fractional requirement). * Not a previous participant on this protocol for subsequent courses. Exclusion Criteria: * Participants bound to a wheelchair. * Participants unable to ambulate independently (needing assistance of cane or walker).
Contact & Investigator
Julian Hong, MD, MS
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06587100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06587100 currently recruiting?
Yes, NCT06587100 is actively recruiting participants. Contact the research team at Imani.Dunn@ucsf.edu for enrollment information.
Where is the NCT06587100 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06587100 clinical trial?
NCT06587100 is sponsored by University of California, San Francisco. The principal investigator is Julian Hong, MD, MS at University of California, San Francisco. The trial plans to enroll 260 participants.